Navigation Links
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Date:8/28/2009

DEERFIELD, Ill. and OSAKA, Japan, Aug. 28 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

The alogliptin New Drug Application (NDA) was submitted in December 2007, and in the complete response for alogliptin dated June 26, 2009, the FDA requested an additional CV safety trial that satisfies the criteria outlined in the December 2008 "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes." The EXAMINE study is designed to comply with this Guidance.

"Takeda received FDA agreement to the design of the CV study and we are pleased to move forward with the study and collecting additional safety data so that the FDA can continue the review of the alogliptin NDA," said Nancy Joseph-Ridge, M.D., General Manager, Pharmaceutical Development Division. "We are committed to conducting this study to satisfy the CV safety requirements, leading to the enhancement of the product profile of alogliptin. While this trial is dependent on the occurrence of CV events, at this point we anticipate that we will be able to submit interim results to the FDA approximately two years after the study begins that will meet the FDA Guidance criteria for drug
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
11. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 CVS Health ... conference call on Friday, May 1, 2015, at 8:30 ... first quarter financial results. An audio webcast ... the Investor Relations portion of the CVS Health website ... http://investors.cvshealth.com . This webcast will be archived and ...
(Date:4/17/2015)... , April 17, 2015  Trovagene, Inc., ... announced today that clinical data presented at the ... its urine-based Precision Cancer Monitoring ℠ (PCM) ... monitoring of EGFR T790M mutations in ... Detection of EGFR T790M Mutation in Urinary Circulating ...
(Date:4/17/2015)... YORK , April 17, 2015  Over the next ... to continue to grow, with ArcView predicting that 14 more ... legalize medical marijuana. The U.S. market for legal cannabis grew ... billion in 2013. Analysts project the market could grow more ... assuming more states soften their stance on marijuana. ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2
... 9, 2011 Reportlinker.com announces that a new ... Omega-3-acid ethyl esters - Comprehensive ... Eliminate unnecessary risk with the industry ... Developer is a regularly updated, professional patent search ...
... Telik, Inc. (Nasdaq: TELK ) today announced that ... overview at the 13th Annual BIO CEO & Investor Conference ... p.m. Eastern time (12:00 p.m. Pacific time), in the Waldorf-Astoria ... presentation will be available on the Telik website, www.telik.com ...
Cached Medicine Technology:Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 2Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 3Reportlinker Adds Omega-3-acid ethyl esters - Comprehensive patent search 4
(Date:4/18/2015)... 2015 Review of Ophthalmology magazine and ... for Success’ program for cataract surgeons attending the American ... Diego, where eye surgeon Jeffrey L. Martin, MD will ... Dr. Martin is the Managing Partner of North Shore ... Dr. Martin to lead this year’s discussion on the ...
(Date:4/18/2015)... April 18, 2015 Lowcostcarinsuranceprice.com has released ... rates have on auto insurance prices . ... rates of vehicle theft may have to pay more ... liability auto insurance policies can also offer protection against ... now be compared online on a single website: ...
(Date:4/18/2015)... NC (PRWEB) April 18, 2015 Patients ... risk of developing mesothelioma later in life, but the ... from mesothelioma that is unrelated to radiation. Surviving Mesothelioma ... on its website. Click here to read it ... Australia compared the cases of 45 patients who had ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... New York, NY (PRWEB) April 18, 2015 ... their Internal Security Threat Report , which they say, “exposes ... on how many new malware variants were introduced in 2014 ... it took for Zero Day threats to be identified and ... – it is abundantly clear that doing business in a ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... and money to properly treat a growing number of ... report out Friday . ,"The military system ... adequately support the psychological health of service members and ... year-long Pentagon mental health task force report: "An Achievable ...
... an industrial chemical found in anti-freeze into its products ... potentially dangerous substance . ,Shanghai White Cat, ... financial hub's oldest companies, said in a statement released ... diethylene glycol, or DEG. The Shanghai-listed firm said the ...
... car rental service to reduce pollution and traffic in the capital, ... of eco-friendly vehicles will be made available before the end of ... be dropped off at various sites set up in Paris, Delanoe ... ,"The idea is that you won't have to use a car ...
... Bordeaux next week safe in the knowledge that the number ... United States and in emerging markets such as China, ... 144 nations and opens June 18, is also comforted by ... thus driving up prices. A survey carried out for Vinexpo ...
... Tens of thousands Saturday staged the Gay Pride parade ... to grant homosexual couples legal status and override Vatican ... which included transvestites and lawmakers, marched under a baking ... of Saint John Lateran, the official ecclesiastical seat of ...
... be getting back together. ,The singer is said ... the sake of their two young sons - Sean Preston and ... now talking things through and that Britney has spent two nights ... want two divorces behind her at her age. She and ...
Cached Medicine News:Health News:War Veterans Lack Adequate Mental Health Care: Pentagon Report 2Health News:Wine Woos World as Trade Fair Opens 2Health News:Wine Woos World as Trade Fair Opens 3Health News:Gay Pride Attracts Tens of Thousands in Rome 2
Long handle occluders are approximately 9 inches long....
Basic external reading model....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: